Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Astrazeneca plc
Headquarters: Cambridge, United Kingdom
Website: http://www.astrazeneca.com
Year Founded: 1999
Status: Public
Industry Sector: HealthTechnology
CEO: Pascal Soriot, MBA, DVM
Number Of Employees: 94,300
Enterprise Value: $230,191,883,733
PE Ratio: 31.46
Exchange/Ticker 1: LSE:AZN
Exchange/Ticker 2: NASDAQ:AZN
Latest Market Cap: $224,137,102,653
BioCentury | Mar 27, 2025
Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
BioCentury | Mar 26, 2025
Data Byte
China deals look beyond cancer
At least eight East-to-West licensing deals outside oncology so far this year
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Mar 24, 2025
Data Byte
Petrelintide up front shatters biotech deal record
At nearly $1.7B, Zealand got $300M more than the prior top cash payment
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Mar 19, 2025
Discovery & Translation
Science Spotlight: TGFβ drives long COVID inflammation via EBV
BioCentury’s roundup of translational innovations also includes boosting T cell antitumor activity via fructose, and a new Parkinson’s risk gene
BioCentury | Mar 19, 2025
Product Development
Acquired assets deliver positive clinical data for Astrazeneca, Genmab: Clinical Report
Plus: A look at recent stock moves on clinical developments
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Mar 12, 2025
Product Development
Autoimmune CAR T companies compete for resources
Crowding in the autoimmune CAR T field brings recruitment challenges
BioCentury | Mar 12, 2025
Product Development
What Arvinas’ data say about target selection
Focusing on the crowded SERD space left little room for differentiation
Items per page:
1 - 10 of 5984